Drugs / Ad5-EBOV
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02533791 | Jul → Sep 2015 | Ebola hemorrhagic fever | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 1 | NCT02401373 | Mar → Jul 2015 | Ebola hemorrhagic fever | First Affiliated Hospital of Zhejiang University | Completed | No outcome recorded |
| Phase 1 | NCT02326194 | Dec 2014 → Feb 2015 | Ebola hemorrhagic fever | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02575456 | Oct 2015 → Jun 2016 | Ebola hemorrhagic fever | Jiangsu Province Centers for Disease Control and Prevention | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad5-EBOV | “A Single-Center, Randomized, Blind, Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Adenovirus Type 5 Vector Based Ebola Virus Disease Vaccine...” NCT02575456 ↗ |
| Known as | Ebola Zaire vaccine | “4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)” NCT02533791 ↗ |
| Modality | Vaccine | “This investigational Ad5-EBOV vaccine was developed according to the 2014 epidemic Zaire strain” NCT02326194 ↗ |
| Route | Intramuscular | “received an initial dose of intramuscular adenovirus type-5 Ebola virus vaccine” PMID 28017642 ↗ Dec 2016 |